Opioid maintenance patients who used cannabis had 2.7-fold higher buprenorphine blood levels than non-users at the same dose, due to cannabis inhibiting the CYP3A4 enzyme that metabolizes the drug.
Addiction medicine providers prescribing buprenorphine, or patients on buprenorphine who also use cannabis.
2.7xHigher buprenorphine blood levels in cannabis users vs non-users at the same dose
What the researchers found
Among opioid maintenance therapy patients on buprenorphine, those who also used cannabis had dramatically different pharmacokinetics. Cannabis users had 2.7-fold higher buprenorphine blood concentrations (p < 0.01) and 1.4-fold higher norbuprenorphine (the active metabolite) compared to non-users receiving the same dose.
The metabolite-to-parent drug ratio told the clearest story: 0.98 in non-users versus 0.38 in cannabis users (p = 0.02). Cannabis was blocking the CYP3A4 enzyme that converts buprenorphine to norbuprenorphine, causing the parent drug to accumulate in the blood. This wasn't a subtle effect — it was a nearly 3-fold difference in drug exposure at identical doses.
Sex did not significantly modify the interaction. The clinical implication was direct: opioid maintenance patients who use cannabis are effectively getting a higher dose than prescribed, with potential consequences for both efficacy and side effects.
Why it matters
Cannabis use among opioid maintenance patients is extremely common — by some estimates, the majority use cannabis at least occasionally. This study showed that combination isn't pharmacologically neutral: cannabis nearly triples buprenorphine blood levels. For a medication with a ceiling effect on respiratory depression (which is why buprenorphine is considered safer than methadone), this might matter less for overdose risk. But it could affect sedation, cognition, treatment compliance, and how doses are adjusted.
This is a concrete, clinically actionable drug interaction that most addiction medicine prescribers aren't accounting for.
The numbers in context
• Buprenorphine levels: 2.7x higher in cannabis users (p < 0.01)
• Norbuprenorphine levels: 1.4x higher in cannabis users (p = 0.07)
• Metabolite-to-parent ratio: 0.98 (non-users) vs 0.38 (users), p = 0.02
• Cannabis users (n=15) vs non-users (n=17), similar prescribed doses
How the study worked
Retrospective analysis of liver-healthy opioid maintenance therapy patients at a German addiction treatment center. Compared buprenorphine and norbuprenorphine blood concentrations in cannabis users (n=15) vs non-users (n=17). Patients with additional illicit drugs or CYP3A-affecting medications were excluded. Cannabis use confirmed via urinalysis.
Who was studied
N=32 opioid maintenance therapy patients, liver healthy, Germany
What this study cannot tell us
Small sample size (32 total patients). Retrospective design with potential confounders. Cannabis use was confirmed by urinalysis but dose and frequency weren't quantified. Only buprenorphine studied — the interaction may differ for methadone (which uses different metabolic pathways). German treatment setting may not generalize to other countries' protocols.
How to read the evidence
Retrospective cohort with small but clean sample. Strong pharmacokinetic finding, limited by sample size and observational design.
When this study was published
Published in 2021. Buprenorphine-cannabis interaction guidelines have not yet been widely adopted in clinical practice.
The bigger picture
This study adds to the drug interaction evidence from RTHC-00059, RTHC-00067, and RTHC-00070. But it's the most clinically urgent of the group: opioid maintenance therapy patients are among the most medically vulnerable cannabis users, and the interaction is among the largest documented. The 2.7-fold difference is in the range where dose adjustments would normally be considered.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Should buprenorphine doses be reduced in patients who use cannabis regularly?
- Does this interaction affect treatment retention or relapse rates?
- Does the interaction vary with cannabis dose or frequency of use?
Common questions
Does cannabis affect buprenorphine treatment?
Is this dangerous?
Read the original research
Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy.
European archives of psychiatry and clinical neuroscience, 271(5), 847-856
The European Archives of Psychiatry and Clinical Neuroscience is a reputable journal focusing on psychiatric and neurological research.
Citation
Vierke, Christopher; Marxen, Brigitte; Boettcher, Michael; Hiemke, Christoph; Havemann-Reinecke, Ursula. (2021). Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy.. European archives of psychiatry and clinical neuroscience, 271(5), 847-856. https://doi.org/10.1007/s00406-019-01091-0
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk